Abstract
Meeting abstracts Immune checkpoints blockade inhibitors, such as anti-CTLA-4 and anti-PD-1, are now proven effective cancer treatments. In melanoma, the patients who experience clinical benefits usually have T cell-inflamed tumor microenvironment. Understanding the molecular mechanism explaining
Highlights
Immune checkpoints blockade inhibitors, such as antiCTLA-4 and anti-PD-1, are proven effective cancer treatments
Understanding the molecular mechanism explaining lack of T cell infiltration in a major subset of patients should lead to development of new therapeutic strategies that improve spontaneous T cell infiltration into tumors and render these patients responsive to immunotherapies
It has been proposed that the T cell-inflamed and non-T cell inflamed phenotypes might be due to the differential expression of immunogenic antigens
Summary
Immune checkpoints blockade inhibitors, such as antiCTLA-4 and anti-PD-1, are proven effective cancer treatments. Density of immunogenic antigens does not explain presence or absence of the T cellinflamed tumor microenvironment in metastatic melanoma From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
